ScholarIQanswers from OpenAlex & ORCID
Elisabeth Buchdunger
ResearcherPublications, citations & collaboration network
Elisabeth Buchdunger is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Elisabeth Buchdunger have?
ScholarIQindexed works
Elisabeth Buchdunger has 82 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Elisabeth Buchdunger have?
ScholarIQcitation count
Elisabeth Buchdunger has 23,999 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Elisabeth Buchdunger?
ScholarIQh-index
Elisabeth Buchdunger has an h-index of 47 in OpenAlex.
What is the i10-index of Elisabeth Buchdunger?
ScholarIQi10-index
Elisabeth Buchdunger has an i10-index of 63 in OpenAlex.
What is the OpenAlex record for Elisabeth Buchdunger?
ScholarIQopenalex
The OpenAlex for Elisabeth Buchdunger is on the source record.
What are the most-cited papers on Elisabeth Buchdunger?
ScholarIQmost cited works
Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.
Christiane J. Bruns, Carmen C. Solórzano, Matthew T. Harbison, Shutaro Ozawa, Rachel Tsan, Dominic Fan, James L. Abbruzzese, Peter Traxler, Elisabeth Buchdunger, Robert Radinsky, Isaiah J. Fidler
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia
Yiguo Hu, Yuhua Liu, Shawn D. Pelletier, Elisabeth Buchdunger, Markus Warmuth, Doriano Fabbro, Michael Hallek, Richard A. Van Etten, Shaoguang Li